Re: the microenvironment and angiogenesis, how does imatinib inhibit tumorigenesis?
By targeting kinases such as bcr-abl kinase, c-KIT tyrosine kinase, and the platelet-derived growth factor (PDGF) tyrosine-kinase
(Therapeutic targeting of the tumor microenvironment has been developed. Most of these agents are in phase I or II clinical trials, but one has been approved by the FDA. Imatinib, initially named signal transduction inhibitor-571 (STI-571), targets pericytes and stromal fibroblasts, and is a specific blocker of bcr-abl kinase, c-KIT tyrosine kinase, and the platelet-derived growth factor (PDGF) tyrosine-kinase receptor. Initially approved for use in patients with chronic myeloid leukemia, currently a phase II clinical trial is investigating the affect of docetaxel plus imatinib in metastatic breast cancer. Such agents hold promise in a multimodal approach to treatment.)